Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-07-31
2000-09-19
Rotman, Alan L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514284, 546 75, 546 77, A61K 31435, C07D22118
Patent
active
06121275&
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
DNA topoisomerases represent a unique class of nuclear enzymes that alter the topological state of DNA by breaking and rejoining the phosphodiester backbone of DNA. Mammalian topoisomerase I is capable of altering the topology of DNA by transiently breaking one DNA strand, while topoisomerase II acts by causing double-strand breaks. Topoisomerase poisoning has recently been recognized as an attractive pharmacological target for the development of novel cancer chemotherapeutic agents. Alkaloids and their derivatives have been investigated as potential antitumor agents, including camptothecin and berberine (Hahn et al., Antibiotics, Vol. 3, Gottlieb et al. (eds.), Springer: New York, pp 577-584 (1975); Shideman, Bull. Natl. Formulary Committee, 18:3 (1950); Bhakkuni et al., The Alkaloids; Vol. 28, Brossi, A. (ed.), Academic Press: New York, pp 95-181 (1986); Suffness et al., The Alkaloids; Vol. XXV, Brossi, A. (ed.); Academic Press: New York, pp 178-197 (1985)).
Extensive studies of camptothecin and its derivatives have established that cellular topoisomerase I is the molecular target for the antitumor alkaloid camptothecin (Hsiang et al., Cancer Res. 48:1722-1726 (1988)). However, some lines of tumor cells have demonstrated resistance to camptothecin.
The demonstration that topoisomerase I is the molecular target for camptothecin has stimulated further identification and development of other topoisomerase I-targeting antitumor compounds (topoisomerase I poisons). Among these are actinomycin D, morpholinodoxorubicin, DNA minor groove binding bis- and tris-benzimidazoles, indolocarbazole derivatives, bulgarein, intoplicine, saintopin, indoloquinolinediones, nitidine derivatives and berberine derivatives. Many of these compounds are also dual poisons of both topoisomerase I and II. Although the number of new topoisomerase I poisons is increasing rapidly, except for camptothecin, topoisomerase I-poisoning has not been demonstrated to be responsible for cell killing for any of the new poisons. Similarly, it is unclear whether the intercalative mode of DNA binding, which is known to be essential for topoisomerase II poisoning, is responsible for poisoning topoisomerase I for the dual poisons.
Many studies have focused their attention on a widely distributed class of alkaloids, whose structures are related to the isoquinoline ring. Two of these compounds, the benzophenanthridine, nitidine, and the related alkaloid fagaronine have a high potency in inducing topoisomerase I-mediated DNA cleavage in vitro (Wang et al., Chem. Res. Toxicol. 6:813-818 (1993)). Several compounds belonging to the family of protoberberines, which are known for their antitumor activities in animals, have also been shown to be topoisomerase I poisons. Berberine represents one of the most intensively studied of the naturally-occurring protoberberine alkaloids and is reported to exhibit weak antitumor activity against P-388 leukemia in mice (Suffness et al., The Alkaloids, Vol. XXV, Brossi, A. (ed.), Academic Press: New York, pp 178-197 (1985)).
Coralyne, an alkaloid analog of protoberberine, has more pronounced antitumor activity relative to berberine, exhibiting significant activity in vivo in mice against L1210 and P388 leukemias (Zee-Cheng et al., J. Med. Chem. 17:347 (1974); Zee-Cheng et al., J. Med. Chem. 19:882 (1976)). While the molecular basis for its antitumor activity has not been identified, it has been speculated that the ability to bind to duplex and triplex DNA may contribute to the observed antileukemic activity (Wilson et al., J. Med. Chem. 19:1261 (1976); Lee et al., Biochemistry 32:5591-5597 (1993)). The antitumor activity of coralyne, coupled with its relatively low toxicity, prompted studies on the synthesis of a number of derivatives (Zee-Cheng et al., J. Med. Chem. 17:347 (1974)), and have suggested that the presence of the methyl substituent at the 8-position and unsaturation at the 5,6-position of coralyne are strongly associated with their antitumor activity against L1210 and P388 leukemia
REFERENCES:
patent: 26065 (1966-07-01), Marvel et al.
patent: 2985661 (1961-05-01), Hien et al.
patent: 3449330 (1969-06-01), Guglielmetti et al.
patent: 3538097 (1970-11-01), Lowe et al.
patent: 3912740 (1975-10-01), Zee-Chang et al.
patent: 4938949 (1990-07-01), Borch et al.
patent: 5106863 (1992-04-01), Hajos et al.
patent: 5126351 (1992-06-01), Luzzio et al.
patent: 5318976 (1994-06-01), Luzzi et al.
patent: 5767142 (1998-06-01), La Voie et al.
patent: 5770617 (1998-06-01), LaVoie et al.
patent: 5807874 (1998-09-01), LaVoie et al.
Coralyne and Related Compounds . . .; Darshan Makhey et al, Apr. 1996.
Enzyme Inhibition VI . . . ;Manohar Sethi, May 1982.
Yadagiri, B., et al., "Convenient Routes to Substituted Benzimidazoles and Imidazolo [4,5-b] Pyridines Using Nitrobenzene as Oxidant", Synthetic Communications, 20 (7), 955-963, (1990).
Yamamoto, Y., et al., "Reaction of 6H-1, 3-oxazin-6-one with Benzyne Giving Isoquinoline derivatives", Chemical Abstracts, vol. 118, No. 7, Abstract No. 59563, (Feb. 15, 1993).
Yamashita, Y., et al., "Induction of Mammalian DNA Topoisomerase I and II Mediated DNA Cleavage by Saintopin, a New Antitumor Agent from Fungus", Biochemistry, vol. 30, 5838-5845, (1991).
Yamashita, Y., et al., "Induction of Mammalian DNA Topoisomerase I Mediated DNA Cleavage by Antitumor Indolocarbazole Derivatives", Biochemistry, vol. 31, 12069-12075, (1992).
Singh, M.P., et al., "Synthesis and Sequence-Specific DNA Binding of a Topoisomerase Inhibitory Analog of Hoechst 33258 Designed for Altered Base and Sequence Recognition", Chem. Res. Toxicol., 5, 597-607, (1992).
Sotomayor, N., et al., "Oxidation Reactions of 2'-functionalized 3-aryltetrahydro-and 3,4-dihydroisoquinolines", Chemical Abstracts, vol. 124, No. 11, Abstract No. 145854, 1227. (Mar. 11, 1996).
Sun, Q., et al., "Structure Activity of Novel Topoisomerase I Inhibitors Related to Hoechst 33342", Abstract 6, American Assn. of Pharmaceutical Scientists, Eastern Regional Meeting, 25, (1995).
Sun, Q., et al., "Structure Activity of Topoisomerase I Poisons Related to Hoechst 33342", Bioorganic & Medicinal Chemistry Letters, vol. 4, 2871-2876, (1994).
Sun, Q., et al., "Structure-activity Studies Related to Minor Groove-Binding Ligands which Inhibit Mammalian DNA Topoisomerase I", Cancer Institute of New Jersey, First Annual Scientific Retreat, Jun. 7, 1994, Princeton Marriott Forrestal Village, Princeton, New Jersey, 66, (1994).
Sun, Q., et al., "Synthesis and Evaluation of Terbenzimidazoles as Topoisomerase I Inhibitors", Chemical Abstracts, 123 (15), Abstract No. 198740.
Sun, Q., et al., "Synthesis and Pharmacological Evaluation of a Series of Novel DNA Topoisomerase I Inhibitors as Antitumor Agents", 86th Annual meeting of the American Association for Cancer Research, Toronto, Ontario, Canada, 2688, (1995).
Sun, Q., et al., "Synthesis and Pharmacological Evaluation of a Series of Novel DNA Topoisomerase I Inhibitors as Antitumor Agents", Abstract 5, 3rd Annual Scientific Retreat, Cancer Institute of New Jersey, 27, (1995).
Sun, Q., et al., "Synthesis of Benzimidazo [2,1-a] Isoquinolines and 5,6-Dihydrobenzimidazo [2,1-a] isoquinolines", Syn. Lett., submitted, (1995).
Walterova, D., et al., "Isolation, Chemistry and Biology of Alkaloids from Plants of Papaveraceae. Part XCV. Practical Application of Isotachophoresis in Analysis of Isoquinoline Alkaloids", Chemical Abstract vol. 104, No. 12, Abstract No. 95573, 454, (1986).
Peters, D., et al., "Synthesis of Various 5-Substituted Uracils", J. Heterocyclic Chem., 27, 2165-2173, (Nov. Dec. 1990).
Pilch, D.S., et al., "Biophysical Characterization of a Cytotoxic, Topoisomerase I Poison", Abstract 8, 3rd Annual Scientific Retreat, Cancer Institute of New Jersey, 3, (1995).
Pilch, D.S., et al., "Characterizing the DNA Binding Modes of a Topoisomerase I-poisoning Terbenzimidazole: Evidence for both Intercalative and Minor Groove Binding Properties", Drug Design and Discovery, vol. 13, 115-133. (1996).
Piper, J.R., et al., "Synthesis and Antifola
LaVoie Edmond J.
Liu Leroy Fong
Makhey Darshan B.
Desai Rita
Rotman Alan L.
Rutgers The State University of New Jersey
LandOfFree
Coralyne analogs as topoisomerase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Coralyne analogs as topoisomerase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Coralyne analogs as topoisomerase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1073507